Pretreatment with Esketamine Reduces Etomidate-Induced Myoclonus During the Induction of Anesthesia: A Randomized Controlled Trial
Therapeutics and Clinical Risk Management · 2024-12 · Volume 20 · 829-836
DOI: 10.2147/tcrm.s485626 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Therapeutics and Clinical Risk Management, 2024-12. Verfasst von Jiang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Myoclonus is a common problem during induction of anesthesia with etomidate. A variety of agents, including opioids and lidocaine, reduced the incidence of myoclonus. However, there is no reported literature evaluating the effect of esketamine pretreatment on etomidate-induced myoclonus. We investigated the influence of pretreatment with esketamine on the incidence of etomidate-induced myoclonus.
Methods
This is a prospective, double-blind, and randomized controlled trial. One hundred patients aged 18-65 scheduled for elective surgery under general anesthesia (including urology surgery, gynaecology surgery, general surgery, and thoracic surgery) were randomly allocated into two groups, each consisting of 50 patients. Esketamine was pretreated with 0.1 mg/kg 60 s before the initiation of etomidate in Group ESK, while normal saline was administered as the placebo (Group C). During the first 1 minute after etomidate administration, myoclonus incidence and severity were assessed. In addition, we measured the hemodynamic changes and side effects of esketamine before administering etomidate.
Results
In group ESK, 14 patients (28%) had myoclonus (degrees of myoclonus: mild 2, moderate 7, severe 5), and 32 patients (64%) in group C (mild 6, moderate 5, severe 21) (P< 0.001). In group ESK, myoclonus incidence and severity were significantly lower than in group C (P< 0.001).
Conclusion
Esketamine 0.1mg/kg IV pretreatment significantly reduce the incidence and the severity of severe myoclonus of etomidate-induced myoclonus without significant adverse effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
ORCID-Profile: Jiang Wang
Zitieren
APA
Wang, J., Zhu, M., Cao, Y., Zhang, L., & Chen, L. (2024). Pretreatment with Esketamine Reduces Etomidate-Induced Myoclonus During the Induction of Anesthesia: A Randomized Controlled Trial. Therapeutics and Clinical Risk Management, Volume 20, 829-836. https://doi.org/10.2147/tcrm.s485626
Vancouver
Wang J, Zhu M, Cao Y, Zhang L, Chen L. Pretreatment with Esketamine Reduces Etomidate-Induced Myoclonus During the Induction of Anesthesia: A Randomized Controlled Trial. Therapeutics and Clinical Risk Management. 2024;Volume 20:829-836. doi:10.2147/tcrm.s485626
BibTeX
@article{Wang2024,
author = {Wang, Jiang and Zhu, Mengmeng and Cao, Yuanyuan and Zhang, Lei and Chen, Lijian},
title = {Pretreatment with Esketamine Reduces Etomidate-Induced Myoclonus During the Induction of Anesthesia: A Randomized Controlled Trial},
journal = {Therapeutics and Clinical Risk Management},
year = {2024},
volume = {Volume 20},
pages = {829--836},
doi = {10.2147/tcrm.s485626}
}
EUVIMED